Blood Grouping Reagent Market: By Product (Consumables, Instruments), By Technique (PCR-based and Microarray Technique, Assay-Based Techniques, Massively Parallel Sequencing Techniques, Other Techniques), By Test Type (Antibody Screening, HLA Typing, Cross-Matching Tests, ABO Blood Tests, Antigen Typing), By End-user (Hospitals, Blood Banks, Clinical Laboratories) and Geography  

Blood Grouping Reagent Market size was valued at USD 2,541 billion in 2022 and is poised to grow at a CAGR of 7.73% from 2023-29. Blood grouping reagents are solutions used to determine ABO, Rhesus, Kell, and MNS blood groups. These divisions of human blood are all depending on whether or not the red blood cells' surfaces contain particular antigens. In the test, red blood cells that carry a specific antigen clump together as a result of the reagents indicating positive results. One of the main drivers of the blood grouping market is the rising need for organ and blood transplants. According to the American Red Cross, an estimated 6.8 million people in the U.S. donate blood with almost 13.6 million units of whole blood and RBCs collected in a year further increasing the blood grouping market. The increased number of patients with platelet erectile dysfunction like thrombocytopenia, cancer, myeloproliferative disorders (MPDs), myelodysplasia, and paraproteinemia is expected to create lucrative opportunities for further development in the market owing to the imperative need for surgeons and doctors to detect the biochemical composition to form a link between disease and druggable target.

Based on the technique outlook, PCR-based and microarray techniques are dominating the market owing to the low cost, ease, and versatility in, in vitro methods for amplifying defined target RBC polymorphic regions. Moreover, the prevalence of anaemia, kidney diseases, and increased accident rates have created a large demand for the blood grouping market. According to WHO, 1.3 million people die each year, along with 20-50 million people suffering injuries, with many incurring a disability as a result of injury from road traffic crashes further increasing the demand for blood grouping reagent market. Furthermore, based on test type, antibody screening is used extensively for documenting exposure to infectious agents, assessing immune status to microorganisms determining the cause of a transfusion reaction of an organ transplant, and tracking the gradual progression of infection or autoimmune disease. The development of new infrastructure, urbanization, and the rise in government campaigns to raise public awareness of the benefits of voluntary blood and organ donations have led to the burgeon of the blood-g grouping reagent market. Furthermore, the rising prevalence of chronic diseases and the accelerating demand for early detection by blood grouping is leading to market growth.

Blood Grouping Reagents Market Key Developments:

• In July 2021, PerkinElmer acquired BioLegend, a leading developer of antibodies and other research tools, by signing a $5.25 Billion deal becoming a significant supplier of reagents and supplies for the development of diagnostic tests and precision medicine.
• In October 2020, Alba Bioscience Limited received approval from FDA for ALBAclone Anti-C (Human/Murine Monoclonal), ALBAclone, Anti-e, (Human/Murine Monoclonal), and ALBAclone Anti-Cw (Human/Murine Monoclonal).